Ranbaxy Wins FDA Approval for Generic Migraine Drug

Ranbaxy Laboratories has received final approval from FDA to manufacture and market sumatriptan succinate tablets, 25mg, and 50mg.

The Office of Generic Drugs, FDA, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Imitrex by GlaxoSmithKline.

According to Ranbaxy, sumatriptan succinate 25mg and 50mg tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

 

Comments

Popular posts from this blog

Trump wants more mental health care; Alabama says it's trying

Smokefree Mumbai campaign responds to recent study by BCM, Houston that claims smoking create stronger memory